Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($1.24), in-line with the analyst estimate of ($1.24). Revenue for the quarter came in at $11.13 million versus the consensus estimate of $8.78 million.

• Fourth quarter and full year 2020 total product and service revenue of $10.2 million and $13.3 million, respectively
• First full quarter of RHA® Collection of dermal fillers revenue of $10.0 million
• Exited 2020 with over $200 million in annualized HintMD processing volume
• Cash, cash equivalents and short-term investments balance of $436.5 million at year-end, with cash into 2024
• Today announced positive data from JUNIPER Phase 2 Trial of DaxibotulinumtoxinA for Injection for adult upper limb spasticity

“The encouraging results from our first full commercial quarter underscore our innovative and differentiated aesthetics portfolio and the traction we are generating with our targeted, prestige launch strategy,” said Mark Foley, President and Chief Executive Officer of Revance. “We believe that more providers and consumers are beginning to recognize Revance as a disrupter in the aesthetics industry and our momentum will accelerate as our innovation pipeline reaches commercialization.”

Foley continued, “Earlier today, we were pleased to announce the positive topline data from our JUNIPER Phase 2 trial, supporting the advancement of DaxibotulinumtoxinA for Injection for the treatment of adult upper limb spasticity. We continue to be encouraged by the efficacy, duration and safety profile of DaxibotulinumtoxinA for Injection across our clinical trials and by the drug’s potential in establishing a new standard of care for treating muscle movement disorders.”

Foley added, “With our strong balance sheet and anticipated milestones ahead, which includes our first BLA approval for DaxibotulinumtoxinA for Injection, a new product extension for the RHA® Collection, the integration of PayFac into the HintMD platform and the completion of our Phase 3 open-label safety study for cervical dystonia, we expect 2021 to be another exciting year for Revance. I’d like to thank the entire team for their hard work and resilience during the challenging COVID-19 environment and for delivering a transformative year.”

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.